Sun Pharma Advanced Research Company Ltd on Monday said its net loss widened to Rs 81.99 crore in the fourth quarter ended March 2023, impacted by higher expenses.
The company had posted a net loss of Rs 71.05 crore in the same period previous fiscal, Sun Pharma Advanced Research Company said in a regulatory filing.
Its revenue from operations stood at Rs 47.69 crore compared to Rs 25.24 crore in the year-ago period, it added.
The total expenses in the fourth quarter were higher at Rs 140.41 crore against Rs 96.51 crore in the same period a year ago.
The company further said that during the quarter, it paused the development of the 'SC0-120' programme due to changing clinical landscape as a result of which it has made provision for committed costs for this programme estimated at Rs 27 crore.
For FY23, the company said its net loss stood at Rs 222.58 crore. It was at Rs 203.4 crore in FY23.
Sun Pharma recalls over 24K pre-filled syringes of generic medication in US
Indian pharma sector set for 'volume to value leadership' journey in 2023
India business to boost pharma, after US sales prove to be a mixed bag
Dr Reddy's, Sun Pharma recall products in US for manufacturing issues
USFDA pulls up Sun Pharma for manufacturing lapses in Halol plant
Sun TV Networks Ltd PAT falls 7.25% to Rs 380.4 cr in March quarter
Crompton Greaves Q4 profit falls 25.4% to Rs 131.5 cr, revenue from ops up
Glenmark posts Q4 net loss at Rs 403 cr on one-time exceptional charge
NTPC logs 6% profit growth in FY23 at Rs 17,197 cr; income rises 34.45%
Arvind SmartSpaces net profit slips 33% to Rs 9.3 crore in Q4 FY23
The revenue from operations in FY23 was Rs 238.78 crore compared to Rs 137.25 crore in FY22.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)